Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Deferoxamine mesylate
Drug ID BADD_D00597
Description Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
Indications and Usage Used to treat acute iron or aluminum toxicity (an excess of aluminum in the body) in certain patients. Also used in certain patients with anemia who must receive many blood transfusions.
Marketing Status approved; investigational
ATC Code V03AC01
DrugBank ID DB00746
KEGG ID D01186
MeSH ID D003676
PubChem ID 62881
TTD Drug ID D0FJ8A
NDC Product Code 60505-6237; 63323-599; 17337-0060; 46014-1127; 46014-1003; 63323-597; 47781-624; 0078-0467; 0409-2337; 60505-6238; 51846-1016; 60505-6236; 68083-172; 68083-173
UNII V9TKO7EO6K
Synonyms Deferoxamine | Desferrioxamine | Desferioximine | Deferoxamine B | Desferrioxamine B | Deferoximine | Deferrioxamine B | Desferroxamine | Desferrioxamine B Mesylate | Mesylate, Desferrioxamine B | Deferoxamine Mesilate | Mesilate, Deferoxamine | Deferoxamine Mesylate | Mesylate, Deferoxamine | Deferoxamine Methanesulfonate | Methanesulfonate, Deferoxamine | Desferal
Chemical Information
Molecular Formula C26H52N6O11S
CAS Registry Number 138-14-7
SMILES CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O.CS(=O)(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Peripheral sensory neuropathy17.09.03.005--
Pruritus23.03.12.001--
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Retinopathy24.03.07.003; 06.10.02.001--
Scab23.03.03.004--Not Available
Shock24.06.02.002--Not Available
Skin irritation23.03.04.009--Not Available
Swelling08.01.03.015--Not Available
Tachycardia02.03.02.007--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Urticaria23.04.02.001; 10.01.06.001--
Vision blurred17.17.01.010; 06.02.06.007--
Visual acuity reduced06.02.10.012; 17.17.01.011--
Visual field defect17.17.01.001; 06.02.07.003--Not Available
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.003--
Localised oedema14.05.06.009; 08.01.07.011; 02.05.04.006--
Eschar24.04.03.024; 23.03.03.027; 12.01.08.008--Not Available
Induration08.01.03.020--Not Available
Motor dysfunction17.01.02.031; 15.05.06.006--Not Available
Blood disorder01.05.01.004--Not Available
Renal impairment20.01.03.010--Not Available
The 2th Page    First    Pre   2    Total 2 Pages